

STATEMENT SHOWING PRILIMINARY TECHNICAL EVALUATION FOR T NO 158-5 (GENERAL MEDICINES)					
S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
1	9M INDIA LIMITED	Technical Evaluation Remarks by DGDCA: S.No. 1 & 2 may be considered after submission of valid product approval			
	1	4038	0.025percentage strength of Triamcinoloneacetonidegel with 15ml/gel	The firm not submittd valid product approval May be considered after submission of product approval	May not be considered
	2	2217	Betahistine Tablets IP 16 mg	The firm not submittd valid product approval May be considered after submission of product approval	May not be considered
	3	1669	Betahistine Tablets IP 8 mg		May be considered
	4	24012410	Digoxin 0.25mg Injection		May be considered
	5	2319	Ketorolac Tromethamine Injection 30mg /ml, 1 ml Ampoule	Item removed form tender	May be considered
	6	417	Lignocaine Hcl Injection IP 5 percentage in 2ml ampoule		May be considered
	7	2336	Lorazepam Injection 2mg/ml, 2ml ampoules		May be considered
	8	1442	Mephentramine Sulphate Injection 30 mg /ml in 10 ml vial		May be considered
	9	441	Metformin Tablets IP 500 mg		May be considered
	10	525	Paracetamol Tablets IP 500mg		May be considered
	11	752	Phenytoin sodium Injection IP 50mg/ml in 5ml vial		May be considered
	12	576	Prednisolone Tablets IP 5mg		May be considered
	13	1172	Trihexyphenidyl Hcl Tablets IP 2mg		May be considered
2	Biodeal Pharmaceuticals Limited	Technical Evaluation Remarks by DGDCA: The firm may be consider for S.No. 2 to 5, 7, 8 and S.No 1 & 6 may be considered after submission of valid product approval			
	1	1705	Alprazolam Tablets IP 0.5 mg	The firm submitted valid product license permitted exclusively to/ marketed by Cadiz and but not submitted parent firm product license it self The product may be considered after submission of the present firm product license	May not be considered
	2	1737	Amisulpride Tablets IP 200mg		May be considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
	3	2217	Betahistine Tablets IP 16 mg		May be considered
	4	1669	Betahistine Tablets IP 8 mg		May be considered
	5	2146	Carbimazole Tablets 20mg	Item removed form tender	May be considered
	6	2246	Clonazepam Tablets 0. 5mg	The firm submitted valid product license permitted exclusively to/ marketed by Cadiz and but not submitted parent firm product license it self The product may be considered after submission of the present firm product license	May not be considered
	7	525	Paracetamol Tablets IP 500mg		May be considered
	8	4020	Tab. Fluoxetine 20 mg		May be considered
3	Biological E. Limited	Technical Evaluation Remarks by DGDCA: May be considered for the product S.No. 1			
		1275.01	Tetanus Vaccine (Adsorbed) IP 0.5ml in Ampoule		May be considered
4	CIPCO PHARMACEUTICALS	Technical Evaluation Remarks by DGDCA: May be considered for the product S.No. 1 to 5			
		2168.03	Iron Folic Acid Tablets Blue Sugar coated Tablets		May be considered
		2168.02	Iron Folic Acid Tablets Red Sugar coated Tablets		May be considered
		441	Metformin Tablets IP 500 mg		May be considered
		525	Paracetamol Tablets IP 500mg		May be considered
		576	Prednisolone Tablets IP 5mg		May be considered
5	CMG BIOTECH PVT LTD	Technical Evaluation Remarks by DGDCA: May be considered for the product S.No. 1 to 8 Except S.No.7 and S.No.7 may be considered after submission for the same product in tablet form			
	1	1737	Amisulpride Tablets IP 200mg		May be considered
	2	2217	Betahistine Tablets IP 16 mg		May be considered
	3	1669	Betahistine Tablets IP 8 mg		May be considered
	4	2246	Clonazepam Tablets 0. 5mg		May be considered
	5	2313	Isosorbide Dinitrate Tablets 10mg	Item removed form tender	May be considered
	6	441	Metformin Tablets IP 500 mg		May be considered
	7	4020	Tab. Fluoxetine 20 mg	The firm submitted for Capsule May be considered after submission in tablet form	May not be considered
	8	1172	Trihexyphenidyl Hcl Tablets IP 2mg		May be considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
6	Cyano Pharma Private Limited	Technical Evaluation Remarks by DGDCA: May be considered for the product S.No. 1 to 4 and S.No. 5 may be considered after submission of proper product license with the required nomenclature			
	1	2168.03	Iron Folic Acid Tablets Blue Sugar coated Tablets		May be considered
	2	2168.02	Iron Folic Acid Tablets Red Sugar coated Tablets		May be considered
	3	441	Metformin Tablets IP 500 mg		May be considered
	4	525	Paracetamol Tablets IP 500mg		May be considered
	5	104	Povidone Iodine Scrub IP 7.5Percentage W/V,500ml pet bottle	The firm submitted product license for Solution not for the Scrub May be considered after submission of proper product license with the required nomenclature	May not be considered
7	Eurokem Laboratories Pvt Ltd.	Technical Evaluation Remarks by DGDCA: May be considered for the product S.No. 1 to 6			
		136	Carbamazepine Tablets IP (Film coated or Extended Release) 100mg	Item removed form tender	May be considered
		2313	Isosorbide Dinitrate Tablets 10mg	Item removed form tender	May be considered
		441	Metformin Tablets IP 500 mg		May be considered
		525	Paracetamol Tablets IP 500mg		May be considered
		13122313	Pentoxiphylline 400mg Tablet		May be considered
		1172	Trihexyphenidyl Hcl Tablets IP 2mg		May be considered
8	FREDUN PHARMACEUTICALS LIMITED	Technical Evaluation Remarks by DGDCA: May not be considered since the applicant failed to furnish approved product list having esign/attestation from CA and also Form--25 license copy not produced			
		441	Metformin Tablets IP 500 mg	Pg.no.9, Provided approved list which doesnot contain esign of licensing authority	May not be considered
9	HEALTHY LIFE PHARMA PRIVATE LIMITED	Technical Evaluation Remarks by DGDCA: May be considered for all the eight products mentioned			
		2246	Clonazepam Tablets 0. 5mg		May be considered
		2168.03	Iron Folic Acid Tablets Blue Sugar coated Tablets		May be considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
		2168.02	Iron Folic Acid Tablets Red Sugar coated Tablets		May be considered
		2313	Isosorbide Dinitrate Tablets 10mg	Item removed form tender	May be considered
		441	Metformin Tablets IP 500 mg		May be considered
		525	Paracetamol Tablets IP 500mg		May be considered
		576	Prednisolone Tablets IP 5mg		May be considered
		1172	Trihexyphenidyl Hcl Tablets IP 2mg		May be considered
10	KARNANI PHARMACEUTICALS PVT LTD	Technical Evaluation Remarks by DGDCA: The firm may be considered for S.No. 1 to 4			
		2329	Lignocaine Hydrochloride Gel IP 2 percentage W/v in 50 Gm		May be considered
		441	Metformin Tablets IP 500 mg		May be considered
		525	Paracetamol Tablets IP 500mg		May be considered
		576	Prednisolone Tablets IP 5mg		May be considered
11	NEM LABORATORIES PRIVATE LIMITED	Technical Evaluation Remarks by DGDCA: The firm may be considered for S.No. 1 to 3			
		441	Metformin Tablets IP 500 mg		May be considered
		525	Paracetamol Tablets IP 500mg		May be considered
		576	Prednisolone Tablets IP 5mg		May be considered
12	NESTOR PHARMACEUTICALS LIMITED	Technical Evaluation Remarks by DGDCA: The firm may be considered for S.No. 1 to 6			
		2168.03	Iron Folic Acid Tablets Blue Sugar coated Tablets		May be considered
		2168.02	Iron Folic Acid Tablets Red Sugar coated Tablets		May be considered
		2313	Isosorbide Dinitrate Tablets 10mg	Item removed form tender	May be considered
		441	Metformin Tablets IP 500 mg		May be considered
		525	Paracetamol Tablets IP 500mg		May be considered
		576	Prednisolone Tablets IP 5mg		May be considered
13	Pfizer Limited	Technical Evaluation Remarks by DGDCA: May be considered except the product mentioned at S.No. 1 of which may be considered after obtaining valid product approval			
		576	Prednisolone Tablets IP 5mg	Furnished product license for dispersible tablets	May not be considered
		1172	Trihexyphenidyl Hcl Tablets IP 2mg		May be considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
14	Pinnacle Life Science Private Limited	Technical Evaluation Remarks by DGDCA: Since the approved product list is only valid upto 19/03/2024, the above two products mentioned at S.No. 1 & 2 may be considered after obtaining valid product list			
		441	Metformin Tablets IP 500 mg	Product list is valid only upto 19/03/2024	May not be considered
		525	Paracetamol Tablets IP 500mg	Product list is valid only upto 19/03/2024	May not be considered
15	PULSE PHARMACEUTICALS PRIVATE LIMITED	Technical Evaluation Remarks by DGDCA: Since the product licenses are not enclosed along with Retention licenses, the mentioned all products may not be considered till obtaining the approved list			
		1737	Amisulpride Tablets IP 200mg	Product list is not in par with Retention of licenses. Advised to get the latest list/attested by Licensing Authority.	May not be considered
		2217	Betahistine Tablets IP 16 mg	Product list is not in par with Retention of licenses. Advised to get the latest approved/renewed/retention list	May not be considered
		1669	Betahistine Tablets IP 8 mg	Product list is not in par with Retention of licenses. Advised to get the latest approved/renewed/retention list	May not be considered
16	REVAT LABORATORIES PRIVATE LIMITED	Technical Evaluation Remarks by DGDCA: The firm may be considered for S.No. 1 to 2			
		441	Metformin Tablets IP 500 mg		May be considered
		525	Paracetamol Tablets IP 500mg		May be considered
17	SEEKO BIOTICS	Technical Evaluation Remarks by DGDCA: The firm may be considered for S.No. 1 to 10			
		1737	Amisulpride Tablets IP 200mg		May be considered
		136	Carbamazepine Tablets IP (Film coated or Extended Release) 100mg	Item removed form tender	May be considered
		2146	Carbimazole Tablets 20mg	Item removed form tender	May be considered
		2313	Isosorbide Dinitrate Tablets 10mg	Item removed form tender	May be considered
		441	Metformin Tablets IP 500 mg		May be considered
		2115	Nicorandil Tab 5mg		May be considered
		525	Paracetamol Tablets IP 500mg		May be considered
		576	Prednisolone Tablets IP 5mg		May be considered
		2126	Pregabalin SR Tablet 75mg	Item removed form tender	May be considered

S No	Bidder Name	Item Code	Item Name	Item Remarks	Status
		1172	Trihexyphenidyl Hcl Tablets IP 2mg		May be considered
18	STRIDE ORGANICS PVT LTD	Technical Evaluation Remarks by DGDCA: May be considered except for the products at S.No. 1 & 2 of which may be considered after production of valid product approval			
		2168.03	Iron Folic Acid Tablets Blue Sugar coated Tablets	Provided product approval with Indigo Cermin Colour with enteric coated, Not furnished the product approval for sugar coated	May not be considered
		2168.02	Iron Folic Acid Tablets Red Sugar coated Tablets	Not furnished the product approval for Red Sugar Coated tablets	May not be considered
		441	Metformin Tablets IP 500 mg		May be considered
		525	Paracetamol Tablets IP 500mg		May be considered
19	WALLACE PHARMACEUTICALS PVT LTD	Technical Evaluation Remarks by DGDCA: The firm may be considered for S.No. 1			
		441	Metformin Tablets IP 500 mg		May be considered
Note: All the bidders are hereby requested to verify the Provisional Technical Evaluation Report and submit their supporting documents on or before 05.00PM on 03.06.2024 to the email id: tenders.apmsidc@gmail.com with Subject : Reply to T No 158-5 (General Medicines) TEC Report					